YKL-40 in patients with end-stage renal disease receiving haemodialysis.
Nielsen, Ture Lange; Plesner, Louis Lind; Warming, Peder Emil; Pallisgaard, Jannik Langtved; Dalsgaard, Morten; Schou, Morten; Høst, Ulla; Rydahl, Casper; Brandi, Lisbet; Køber, Lars; Johansen, Julia Sidenius; Kastrup, Jens; Iversen, Kasper Karmark.
; 23(4): 357-363, 2018 May - Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29357700
Elevated serum YKL-40 levels in patients with Kawasaki disease.
Serum sclerostin: relation with mortality and impact of hemodiafiltration.
Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study.
Immunosuppressive agents for treating IgA nephropathy.
Determinants of N-terminal pro-brain natriuretic peptide variation in hemodialysis patients and prediction of survival.
Troponin I and NT-proBNP and the association of systolic blood pressure with outcomes in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study.
Serum Ferritin Variations and Mortality in Incident Hemodialysis Patients.
Circulating resistin is a significant predictor of mortality independently from cardiovascular comorbidities in elderly, non-diabetic subjects with chronic kidney disease.
Pre-End-Stage Renal Disease Hemoglobin Variability Predicts Post-End-Stage Renal Disease Mortality in Patients Transitioning to Dialysis.
Bicarbonate Balance and Prescription in ESRD.